#ATS2018 — Prometic’s PBI-4050, Ryplazim Have Potential to Prevent Lung Fibrosis, Latest Data Show

#ATS2018 — Pamrevlumab Slows Fibrosis Progression, Improves Lung Function in IPF, Phase 2 Trial Shows

Investigational Pamrevlumab halts the progression of lung fibrosis and improves lung function in patients with idiopathic pulmonary fibrosis (IPF), new results from the Phase 2 PRAISE trial show. These results were recently presented in a series of poster presentations at the American Thoracic Society (ATS) 2018 in San Diego. “We…

#ATS2018 – Galapagos’ GLPG1690 Prevents Lung Function Decline in IPF Patients, Trial Shows

Treatment candidate GLPG1690 prevented lung function decline in a Phase 2 clinical trial of idiopathic pulmonary fibrosis (IPF) patients, Belgium-based Galapagos announced. The research, “Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised…

What I’ve Learned from Lung Transplant Tests

I shared in a recent column that I’m going through testing for lung transplant consideration. It has been challenging, but I am grateful because I know many pulmonary fibrosis patients do not have this opportunity. Being poked and prodded is exhausting, stressful, and sometimes painful. But it…